This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

LYNPARZA™ (olaparib) prostate cancer patient booklet

This downloadable patient booklet has been designed for HCPs like yourself, to provide your patients already on/or recently prescribed LYNPARZA (olaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

This downloadable resource provides patients prescribed olaparib with useful information on their treatment, potential side effects to look out for and allows them to make a record of any symptoms they experience.

Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.

More information about LYNPARZA™ (olaparib) in mCRPC:

LYNPARZA is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1

References

  1. LYNPARZA (tablets) Summary of Product Characteristics.

Supporting documentation

100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-29707 | Date of Preparation: July 2021